Network analysis of multidimensional symptoms and inflammatory biomarkers in Chinese patients with glioma

Abstract

Purpose Patients with glioma experience multidimensional symptoms that reduce their functional status, quality of life, and survival, and these symptoms may be associated with inflammation. This study applied network analysis to examine and visualize the relationship between multidimensional symptom experiences and inflammatory biomarkers and assess the symptom networks of multidimensional symptom experiences over time in patients with glioma.Methods Participants diagnosed with glioma were recruited and completed the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) at three different time points: 2 days after admission (T1), 7 days after surgery (T2), and 1 month after surgery (T3). On the same day as the T1 questionnaire collection, plasma levels of interleukin-1β (IL-1β), IL-6, IL-10, tumor necrosis factor-α (TNF-α), and c-reactive protein (CRP) were measured. Network analysis was employed to explore the relationships among multidimensional symptom experiences and inflammatory biomarkers of patients.Results Of the total 334 participants (mean age 54.38 ± 13.16 years), 67.1% had high-grade tumors. In the symptom-cytokine network model, there were positive correlations between “sad and IL-6” (0.19), “fatigue and IL-10” (0.07), and “sleepy and IL-1β” (0.06). Regarding the symptom-symptom network models, difficulty remembering (r_s = 1.20), sad (r_s = 1.60), and change in bowel pattern (r_s = 1.30) emerged as the most central symptoms across the three assessments.Conclusions Network analysis provides a novel method for investigating the relationships between multidimensional symptom experiences and inflammatory biomarkers. Additionally, it allows for identifying different core symptoms at various stages of treatment. Nurses should effectively address and manage symptoms by focusing on special core symptoms and their interconnections within the network.Implications for Cancer Survivors Assessing and addressing neurological symptoms, psychological changes, gastrointestinal symptoms early in treatment may improve health outcomes of patients with glioma.